newsfilter
← Latest News
GlobeNewswire·

Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update

Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023On track to